Rein Therapeutics, Inc. made a public disclosure
SEC 8-KRead source ↗
Rein Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders3 buying, 0 selling6 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 41% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Rein Therapeutics, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 88% and a beta of 2.3 against the S&P 500.
Latest results
- Earnings per share
- -$0.10 against an average estimate of -$0.17: beat by 41.2%
- Share reaction
- -1.8% in the first session after the results on May 15, 2025, against +1.1% for the S&P 500
Price chart
- 1 day-5.2%
- 1 week+8.9%
- 1 month-20.7%
- This year-45.3%
- 1 year-59.4%
- 5 years-96.6%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- May 15, 2025
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Announcement
- Shareholder vote
Rein Therapeutics, Inc. reported shareholder vote results
SEC 8-KRead source ↗
No model value for Rein Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Rein Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.14 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Rein Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.46 | +77% | — | 0% |
| Next | −$0.47 | −1% | — | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −71.8% on 90 days ago. In the last 30 days, 1 analyst raised Rein Therapeutics, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$1.63 | −$1.33 |
| 60 days ago | −$0.53 | −$0.50 |
| 30 days ago | −$0.53 | −$0.50 |
| 7 days ago | −$0.44 | −$0.41 |
| Now | −$0.46 | −$0.47 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.17 | −$0.10 | +41.2% |
| Mar 2026 | −$0.49 | −$0.19 | +61.2% |
| Dec 2025 | −$0.21 | −$1.22 | −467.4% |
| Sept 2025 | −$0.24 | −$0.21 | +12.5% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 0.7% of tradable shares
- Days to cover
- 1.39 at average volume
- Short interest, 1 month
- −12% to October 15, 2026
- Held by institutions
- 52% of shares
- Held by insiders
- 5.0% of shares
- Employees
- 10 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| RNTX | −46% | −79% | +29% | −25% | −50% | −45% |
| Industry peers (median) | −35% | −56% | −18% | −29% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| RNTX | 33% | 17% | 50% | 50% | 42% | 46% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| RNTX | −77% | −86% | −64% | −76% | −60% | −71% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since June 29, 2017: 100% from October 4, 2017 to October 19, 2026. Getting back needed a 53922% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $0.55 – $1.88
- From 52-week high
- −66.2%
- vs 50-day average
- −14.6%
- vs 200-day average
- −38.7%
- Volatility (1 year)
- 88%
- Beta vs S&P 500
- 2.26
Share price after results
- Next day
- 0 up, 6 down typical move ±11.9%
- After a week
- 1 up, 5 down typical move ±18.9%
- After a month
- 1 up, 5 down typical move ±29.4%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| May 15, 2025 | −1.8% | +1.1% | −13.8% | −19.1% |
| November 14, 2024 | −19.6% | −1.9% | −27.7% | −40.6% |
| August 14, 2024 | −19.9% | +2.0% | +24.3% | +33.0% |
| May 15, 2024 | −1.3% | +1.0% | −5.1% | −17.4% |
| May 1, 2024 | −16.0% | +0.6% | −19.8% | −29.7% |
| April 15, 2024 | −12.9% | −1.4% | −22.6% | −36.5% |
Fundamentals
Insider trading activity
Full insider history and chart Insider purchases History → $201,804 6 trades by 3 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $201,804 net buying
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Von Rickenbach Josef H Director | May 27, 2026 | Buy | 4,500 | $1.07 | $4,815 |
| Von Rickenbach Josef H Director | May 26, 2026 | Buy | 23,190 | $1.06 | $24,581 |
| Von Rickenbach Josef H Director | May 22, 2026 | Buy | 15,950 | $1.05 | $16,748 |
| Von Rickenbach Josef H Director | May 21, 2026 | Buy | 3,420 | $1.04 | $3,557 |
| Windsor James Brian See Remarks | April 30, 2026 | Buy | 25,000 | $1.00 | $25,000 |
| Voss Value Master Fund, Lp 10% owner | November 14, 2025 | Buy | 104,183 | $1.22 | $127,103 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around August 14, 2025 estimated from the company's past filing pattern, not announced
- May 15, 2025
- November 14, 2024
- August 14, 2024
- May 15, 2024
- May 1, 2024
- April 15, 2024
Recent SEC filings
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 10-Q Quarterly report
- 8-K Current report
- S-1 S-1
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Rein Therapeutics, Inc. in brief
- What does Rein Therapeutics, Inc. do?
- Rein Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Rein Therapeutics, Inc.'s stock ticker?
- Rein Therapeutics, Inc. trades under the ticker RNTX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Are insiders buying or selling Rein Therapeutics, Inc. stock?
- Over the last 12 months, Rein Therapeutics, Inc.'s directors and officers reported 6 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
Follow research on Rein Therapeutics, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.